[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

Exhibit 10.7

Authorized Generic of Makena® (hydroxyprogesterone caproate injection)

________________________________________________________________

DISTRIBUTION AND SUPPLY AGREEMENT

BY and BETWEEN

AMAG PHARMACEUTICALS, INC.

and

PRASCO, LLC

DATED AS OF DECEMBER 20, 2017

_________________________________________________________________

--------------------------------------------------------------------------------

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

DISTRIBUTION AND SUPPLY AGREEMENT

This Distribution and Supply Agreement (this “Agreement”) is made as of December
20, 2017 (the “Effective Date”), by and between AMAG Pharmaceuticals, Inc., a
Delaware corporation with offices located at 1100 Winter Street, Waltham,
Massachusetts 02451 (hereinafter referred to as “Manufacturer” and “AMAG”), and
Prasco, LLC, a Ohio limited liability company with offices located at 6125
Commerce Court, Mason, Ohio 45040 (hereinafter referred to as “Distributor” and
“Prasco”) and is to be effective as of the Effective Date. Manufacturer and
Distributor are each referred to herein as a “Party” and, collectively, as the
“Parties.”

RECITALS
WHEREAS, Manufacturer may supply, and Distributor may purchase, distribute and
sell, the Products in the Territory in accordance with the terms of this
Agreement.

NOW THEREFORE, in consideration of the mutual covenants and consideration set
forth herein, the Parties hereto agree as follows:

ARTICLE 1
DEFINITIONS
As used in this Agreement, the following defined terms shall have the meanings
set out in this Article 1.
1.1    “Act” shall mean the United States Federal Food, Drug, and Cosmetic Act,
as amended from time to time, and the rules, regulations and guidelines
promulgated thereunder.
1.2    “Affiliate” of a Party shall mean a Person that controls, is controlled
by, or is under common control with a Party. For the purposes of this
definition, the word “control” (including, with correlative meaning, the terms
“controlled by” or “under common control with”) means the actual power, either
directly or indirectly through one or more intermediaries, to direct the
management and policies of such Person, whether by the ownership of fifty
percent (50%) or more of the voting interest of such Person (it being understood
that the direct or indirect ownership of a lesser percentage of such interest
shall not necessarily preclude the existence of control), or by contract or
otherwise.
1.3    “AG Product” shall mean a hydroxyprogesterone caproate injection supplied
in (i) 250 mg/mL preservative free in 1 mL single dose glass vial in a single
unit carton bundled with four in each tray or pack, and (ii) 250 mg/mL in 5 mL
multidose glass vial in a single unit carton, each in Manufactured form and sold
under AMAG’s NDA. 
1.4    “Agreement” shall have the meaning assigned to such term in the Preamble.

1.5    “Allowance for Distribution and Marketing” shall mean [***].

1

--------------------------------------------------------------------------------

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

1.6    “AMAG Party” shall have the meaning assigned to such term in Section
9.1(b).
1.7    “AMAG’s NDA” shall mean NDA No. 21-945, and all supplements filed
pursuant to the requirements of FDA, including all documents, data and other
information concerning Makena which are necessary for the Regulatory Approval of
Makena.
1.8    “Bailment Agreement” has the meaning given in Section 6.1(b).
1.9    “Bailment Product” has the meaning given in Section 6.1(b).
1.10    “Bankruptcy Event” shall mean, with respect to a Person, that such
Person becomes insolvent, or voluntary or involuntary proceedings by or against
such Person are instituted in bankruptcy or under any insolvency law, or a
receiver or custodian is appointed for such Person, or proceedings are
instituted by or against such Person for corporate reorganization or the
dissolution of such Person due to such Person becoming insolvent, which
proceedings, if involuntary, shall not have been dismissed within sixty (60)
days after the date of filing, or such Person makes an assignment for the
benefit of its creditors, or substantially all of the assets of such Person are
seized or attached and not released within sixty (60) days thereafter.
1.11    “Branded Product” means branded product Makena® sold by Manufacturer
under the Trademark.
1.12    “Brand Fee” means the “Annual Fee on Branded Prescription Pharmaceutical
Manufacturers and Importers” pursuant to Section 9008 of the Patient Protection
and Affordable Care Act of 2010, and any amendments thereto, that is owed by
Distributor relating to the sale of Products if the orphan drug status of the
Product changes, and shall be calculated on an accrual basis based on sales of
the Products during a period to the relevant government programs.
1.13    “Business Day” shall mean any day other than a Saturday, Sunday or a day
on which banks in New York, New York are authorized or required by law to close.
1.14    “Calendar Quarter” shall mean each three-month period starting on
January 1, April 1, July 1, and October 1 of each calendar year.
1.15    “cGMP” shall mean all applicable standards relating to manufacturing
practices for fine chemicals, active pharmaceutical ingredients, intermediates,
bulk products or finished pharmaceutical products, including the principles
detailed in the U.S. current Good Manufacturing Practices, 21 C.F.R. Parts 210
and 211.
1.16    “Change in Control” shall mean (i) the liquidation or dissolution of a
Party or the sale or other transfer by a Party (excluding transfers to
Affiliates) of all or substantially all of its assets, or (ii) the occurrence of
a tender offer, stock purchase, other stock acquisition, merger, consolidation,
recapitalization, reverse split, sale or transfer of assets or other
transaction, as a result of which any person, entity or group (a) becomes the
beneficial owner, directly or
indirectly, of securities of a Party representing more than fifty percent (50%)
of the ordinary shares of such Party or representing more than fifty percent
(50%) of the combined voting power with respect to the election of directors (or
members of any other governing body) of such

2

--------------------------------------------------------------------------------

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

Party’s then outstanding securities, or (b) obtains the ability to appoint a
majority of the Board of Directors (or other governing body) of a Party, or
obtains the ability to direct the operations or management of a Party or any
successor to the business of a Party.
1.17    “Claim” shall have the meaning assigned to such term in Section 9.1(a).
1.18    “Commencement Date” shall have the meaning assigned to such term in
Section 2.1(b).
1.19    “Commencement Notice” shall have the meaning assigned to such term in
Section 2.1(b).
1.20    “Commercially Reasonable Efforts” shall mean, with respect to the
efforts to be expended by any Party with respect to any objective, those
reasonable, diligent, good faith efforts to accomplish such objective as such
Party would normally use to accomplish a similar objective under similar
circumstances. “Commercially Reasonable Efforts” with respect to a Product shall
mean those efforts and resources normally used by such Party with respect to a
product owned or controlled by such Party, or to which such Party has similar
rights, which product is of similar market potential and is at a similar stage
in its life as is the Product, taking into account issues of safety, efficacy,
product profile, the competitiveness of the marketplace, the proprietary
position of the Product, the regulatory structure involved, profitability of the
Product and other relevant commercial factors. Without limiting the foregoing,
Commercially Reasonable Efforts requires, with respect to such obligations, that
the Party: (a) promptly assign responsibility for such obligation to specific
employee(s) who are held accountable for progress and monitor such progress on
an on-going basis, (b) set annual objectives for carrying out such obligations,
and (c) allocate resources designed to advance progress with respect to such
objectives.
1.21    “Competitive Product” shall mean [***].
1.22    “Compound” shall mean hydroxyprogesterone caproate.
1.23    “Confidential Information” shall mean, with respect to a Party, all
proprietary information of any kind whatsoever (including without limitation,
materials, data, compilations, formulae, models, patent disclosures, procedures,
processes, projections, protocols, results of experimentation and testing,
specifications, strategies, techniques and all non-public intellectual

3

--------------------------------------------------------------------------------

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

property rights) or other information (whether or not patentable) disclosed by a
Party to the other Party regarding a Party’s know how, products, business
information or objectives, regardless of whether such information is written,
oral, electronic or other form and regardless of whether such information is
specifically designated as confidential. This Agreement and the terms and
conditions hereof shall be considered “Confidential Information”.
1.24    “Designated Officers” shall have the meaning assigned to such term in
Section 12.15.
1.25    “Disclosing Party” shall have the meaning assigned to such term in
Section 11.1.
1.26    “Distributor” shall have the meaning assigned to such term in the
Preamble.
1.27    “Distributor Label Information” shall mean the artwork, layout, content
and design provided or included in the Product Labeling, other than the content
of the Makena Label.
1.28    “Distributor Party” shall have the meaning assigned to such term in
Section 9.1(a).
1.29    “Event of Default” shall have the meaning assigned to such term in
Section 10.3.
1.30    “Failure to Supply Charges” shall mean [***].
1.31    “FDA” shall mean the United States Food and Drug Administration and any
agency under its control or any successor agency thereto.
1.32    “FDA Notice” shall have the meaning assigned to such term in Section
10.5(a).
1.33    “Firm Order” shall have the meaning assigned to such term in Section
5.1(c).
1.34    “Firm Order Period” shall have the meaning assigned to such term in
Section 5.1(c).
1.35    “Firm Order Quantity” shall have the meaning assigned to such term in
Section 5.1(c).
1.36    “First Commercial Sale” shall mean the date of Distributor’s first sale
of Product to a Third Party, including without limitation to retail chains,
pharmaceutical wholesalers, or managed care providers.
1.37    “Force Majeure Event” shall have the meaning assigned to such term in
Section 10.6.

4

--------------------------------------------------------------------------------

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

1.38    “GAAP” shall mean generally accepted accounting principles in effect in
the United States from time to time, consistently applied.
1.39    “Generic Equivalent Product” shall mean a Competitive Product approved
by the FDA.
1.40    “Initial Launch Quantities” shall have the meaning assigned to such term
in Section 5.1(b).
1.41    “Initial Term” shall have the meaning assigned to such term in Section
10.1.
1.42    “Invoice Supply Price” shall mean, for Products delivered to
Distributor, [***].
1.43    “Label” shall mean any Package labeling designed and used with the
Product, including the package insert for the Product that is approved by FDA,
and “Labeled” or “Labeling” shall have the correlated meaning.
1.44    “Launch Quantities” shall have the meaning assigned to such term in
Section 5.1(b).
1.45    “Losses” shall mean any liabilities, damages, costs or expenses,
including reasonable attorneys’ fees and expert fees, incurred by any Party that
arise from any claim, lawsuit or other action by a Third Party.
1.46    “Makena” shall mean the branded pharmaceutical product that contains the
Compound as its sole active ingredient which is approved for Marketing in the
Territory pursuant to AMAG’s NDA and sold under the Trademark.
1.47    “Manufacture” shall mean all activities related to the manufacturing
and/or production of the Product, or any ingredient thereof including, but not
limited to, manufacturing and procuring Compound or supplies for development,
manufacturing product for commercial sale, packaging, labeling, in-process and
finished product testing, including QC Testing, release of product or any
component or ingredient thereof, quality assurance activities related to
development, manufacturing and release of product, ongoing stability tests and
regulatory activities related to any of the foregoing, and “Manufactured” and
“Manufacturing” shall have the correlated meaning.
1.48    “Manufacturer” shall have the meaning assigned to such term in the
Preamble.
1.49    “Manufacturing Costs” shall mean [***].

5

--------------------------------------------------------------------------------

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

The current Manufacturing Costs are set forth on Exhibit 1.49.
1.50     “Market” shall mean to distribute, promote, advertise (if applicable),
market, offer to sell and sell, to a Third Party and “Marketing” and “Marketed”
shall have the correlated meaning.
1.51    “Modified Firm Order Quantity” shall have the meaning assigned to such
term in Section 5.1(c).
1.52    “NDA” shall mean a New Drug Application filed with FDA pursuant to
Section 505 of the Act (21 U.S.C. Section 355), or the applicable regulations
(21 CFR Part 314), including any supplements, amendments or modifications
submitted to or required by FDA or any successor application or procedure for
approval to Market a pharmaceutical product.
1.53    “NDC#” shall mean a unique 3-segment number that identifies the
labeler/vendor, the product and the trade package size.
1.54    “Net Distributable Profits” for any period means [***]. Notwithstanding
the foregoing, it is understood that Net Distributable Profits for a particular
period may be adjusted in the future (but not to less than zero) for any
quarterly period in connection with adjustments to the accrual amounts for such
period as actual amounts and/or more definite information becomes known in
accordance with Section 3.4.
1.55    “Net Sales” means [***]. 

6

--------------------------------------------------------------------------------

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

1.56     “Non-performing Party” shall have the meaning assigned to such term in
Section 10.6.
1.57    “Notice” shall have the meaning assigned to such term in Section 12.8.
1.58    “Package” shall mean all containers, including bottles, cartons,
shipping cases or any other matter used in packaging or accompanying a product,
and “Packaged” or “Packaging” shall have the correlated meaning.
1.59    “Party” and “Parties” shall have the meaning assigned to such terms in
the Preamble.
1.60    “Performing Party” shall have the meaning assigned to such term in
Section 10.6.
1.61    “Person” shall mean any individual, corporation, partnership, limited
liability company, joint venture, association, trust, unincorporated
organization or other legal Person or entity.
1.62    “Pharmacovigilance Agreement” shall mean the pharmacovigilance agreement
entered into by the Parties within [***] following the Effective Date of this
Agreement, which agreement shall be on terms that comply with ICH guidelines,
including: (i) providing detailed procedures regarding the maintenance of core
safety information and the exchange of safety data relating to the Compound,
Products, and Makena in the Territory within appropriate timeframes and in an
appropriate format to enable Manufacturer to meet both expedited and periodic
regulatory reporting requirements; and (ii) ensuring compliance with the
reporting requirements of all applicable regulatory authorities in the Territory
for the reporting of

7

--------------------------------------------------------------------------------

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

safety data in accordance with standards stipulated in the ICH guidelines, and
all applicable regulatory and legal requirements regarding the management of
safety data.
1.63    “Pre-booking Activities” shall mean the activities set forth on Exhibit
1.63.
1.64    “Pre-booking Date” shall have the meaning assigned to such term in
Section 2.1(b).
1.65    “Products” shall mean the AG Products supplied to Distributor under this
Agreement, each sold under Distributor’s NDC# and trade dress. 
1.66    “Product Claims” shall have the meaning assigned to such term in Section
6.6(a).
1.67    “Product Listing” shall mean filing with FDA a list of drugs in
commercial distribution as required by law.
1.68    “Promotional Materials” shall have the meaning assigned to such term in
Section 2.4.
1.69    “QC Testing” shall include all quality control tests and other
inspections required by applicable cGMP standards and AMAG’s NDA for each lot of
Product delivered to Distributor.
1.70    “Quality Agreement” shall mean the quality agreement entered into by the
Parties within [***] following the Effective Date of this Agreement, which sets
forth the respective responsibilities of Manufacturer and Distributor to ensure
that the manufacture, quality control, release, storage, distribution, and
reporting obligations for the Product comply with good manufacturing practices
as set forth in 21 CFR 210 and 211 and with the Product marking authorization
held by the Manufacturer.
1.71    “Recipient” shall have the meaning assigned to such term in Section
11.1.
1.72    “Regulatory Approval” shall mean final Marketing approval by FDA for the
Marketing of a pharmaceutical product in the Territory
1.73    “Remaining Supply Price” shall have the meaning assigned to such term in
Section 3.4.
1.74    “Rolling Forecast” shall have the meaning assigned to such term in
Section 5.1(a).
1.75    “Shelf Stock Adjustment” shall mean the customary practice of providing
a purchaser of generic product an adjustment to the net purchase price for
on-hand inventory in response to the lowering of the purchase price for the
generic product.
1.76    “SKU” means a given package configuration of a given strength of the
Products, as may be changed by Manufacturer upon notice to Distributor.

8

--------------------------------------------------------------------------------

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

1.77    “Specifications” shall mean the specifications for the Products
contained in AMAG’s NDA.
1.78    “Supply Interruption” shall have the meaning assigned to such term in
Section 5.2(c).
1.79    “Supply Price” shall mean [***].
1.80    “Term” shall have the meaning assigned to such term in Section 10.1.
1.81    “Territory” shall mean the [***].
1.82    “Third Party” or “Third Parties” shall mean any Person or entity other
than a Party or its Affiliates.
1.83    “Trademark” shall mean the Manufacturer’s trademark Makena®.

ARTICLE 2
DISTRIBUTION RIGHTS AND OBLIGATIONS
2.1    Commencement Date; First Commercial Sale.
(a)    At any time after the Effective Date, Manufacturer may elect to authorize
Distributor to commence the Marketing of a SKU under this Agreement.
Manufacturer shall have the sole right and discretion to determine if and when
to authorize Distributor to commence Marketing the SKU.
(b)    If Manufacturer decides to authorize Distributor to commence Marketing a
SKU, Manufacturer shall provide Distributor with written notice specifying a
date for Distributor to commence selling and distributing the SKU and a date for
Distributor to begin Pre-booking Activities for such SKU. A notice delivered by
Manufacturer under this Section 2.1(b) is referred to herein as a “Commencement
Notice,” the date specified in a Commencement Notice for Distributor to commence
the selling and distribution of a SKU is referred to herein as the “Commencement
Date,” and the date specified in a Commencement Notice or in a separate written
pre-booking notice for Distributor to commence the Pre-booking Activities is
referred to herein as the “Pre-booking Date”.
(c)    Effective as of the Pre-booking Date for a SKU, Manufacturer grants to
Distributor an exclusive, non-sublicensable, nontransferable license under the
NDA for the Branded Product to perform the Pre-booking Activities for such SKU
in the Territory in accordance with the terms of this Agreement. Effective as of
the Commencement Date for a SKU, Manufacturer grants to Distributor an
exclusive, non-sublicensable, nontransferable license under the NDA for the
Branded Product to Market such SKU of the Product in the Territory as a generic
product subject to and in accordance with the terms of this Agreement.
Distributor shall Market the Product in the Territory as a

9

--------------------------------------------------------------------------------

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

generic product commencing as of the Commencement Date, in accordance with this
Agreement. Prior to the Pre-booking Date, Distributor shall have no right to
distribute, Market, promote or sell the Product, engage in Pre-booking
Activities, make any public statements, or inform any Third Parties regarding
Distributor’s right or ability to distribute, or sell the Products. Prior to the
Commencement Date, Distributor shall have no right to distribute or sell the
Product.
(d)    Manufacturer may elect to supply Distributor with some or all of the
Launch Quantities of each SKU under the Bailment Agreement prior to the
Commencement Date for such SKU. In any event, upon delivery of the Commencement
Notice for a SKU, Manufacturer shall promptly supply Launch Quantities of such
SKU to Distributor, to the extent not previously supplied under the Bailment
Agreement.
2.2    Commercial Exploitation.
(a)    Distributor shall [***] Market the Product in the Territory in accordance
with this Agreement. Distributor shall not Market the Product through a Third
Party or Affiliate without the prior written consent of Manufacturer. Except for
Marketing activities, Distributor shall be entitled to carry out all other
obligations under this Agreement through one or more of its Affiliates, but any
such arrangement shall not limit Distributor’s obligations and liability with
respect thereto under this Agreement.
(b)    Distributor shall [***] have the First Commercial Sale for a SKU be
within [***] of the later of [***]. No later than [***] after the First
Commercial Sale of a SKU, Distributor shall give written notice to Manufacturer
specifying the date of the First Commercial Sale of such SKU.
(c)    Distributor shall [***] in entering into contracts, establishing the
terms of sale and Marketing decisions (except as set forth in Section 2.2(c),
2.2(e) 2.4, and 2.5) for the Products, including without limitation the price to
its customers, [***]; provided that Distributor’s contracts and terms of sale
for the Products shall be consistent in all material respects with industry
standards for other similar products (e.g., using similar distribution channels)
distributed by Distributor, including with respect to returns, credits,
discounts, rebates and adjustments. In addition, Distributor will not use the
Products as a “loss leader” or as part of a bundle, basket or group sale with
sales of its other products that would result in financially disadvantaging the
Product relative to such other products.
(d)    In Marketing the Products, Distributor (i) shall not use any trademarks
or trade names owned or licensed by Manufacturer, and (ii) shall identify itself
as the distributor of the Product using its “Prasco” trade name and trade dress.
Within [***] of the Effective Date, Manufacturer shall provide Distributor with
final labeling and packaging artwork, including the graphics and artwork for the
Packaging

10

--------------------------------------------------------------------------------

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

and Labeling components for Distributor’s approval. All trademarks, trade names
and packaging graphics and artwork on the Labeling and Packaging shall comply
with regulatory or other governmental agency guidance or directives. In no event
shall Distributor identify the Products in any way that is deemed by
Manufacturer to be confusingly similar to the trade name Makena.
(e)    Distributor shall not, directly or indirectly, (i) solicit or accept
orders for sales of any Products to any existing or prospective customer outside
the Territory, (ii) deliver or tender (or cause to be delivered or tendered) any
Products outside of the Territory, or (iii) sell any Products to, or solicit any
sales from, a customer if Distributor [***] that such customer intends to resell
the Product outside of the Territory. If Distributor becomes aware, after
reasonable inquiry, of any circumstance where there is a reason to believe that
Products are being, or will be, distributed or redistributed outside the
Territory by a customer of Distributor, Distributor shall promptly notify
Manufacturer, and Distributor shall promptly [***] stop the sale or distribution
of Products outside the Territory, including, without limitation, terminating
future sales of Product to any such customer until such time that Distributor
and/or Manufacturer receives reasonable assurances from such customer that such
activity has stopped and a Party has communicated such reasonable assurance to
the other Party. Distributor shall not sell or otherwise transfer Products to an
Affiliate for subsequent Marketing or resale by such Affiliate.
2.3    Distribution Obligations.
(a)    Distributor shall: (i) store, handle and distribute its inventory of the
Products, including Bailment Product, in clean and sanitary conditions as
required to maintain the quality and traceability of the Product, and in
accordance with FDA approved labeling for the Product; (ii) not alter the
Products in any manner; (iii) comply with the Act and all other applicable
federal, state and local food, health and other relevant laws, rules and
regulations within the Territory in connection with the storage, handling, and
distribution of the Product; and (iv) not Market the Products in any manner
which is inconsistent with FDA approved labeling of the Product or applicable
laws, rules and regulations (including without limitation, 21 CFR Sections 201
and 801), or otherwise not make any false or misleading representations to
customers or others regarding the Product.
(b)    Distributor shall Market the Products using only an NDC# that reflects
Distributor as the distributing and selling party.
(c)    Distributor shall not Market the Products under any brand name or private
label.
(d)    Distributor (or Distributor’s designee) shall at all times maintain its
inventory of Product under proper storage conditions in compliance with all
applicable laws, rules and regulations and in accordance with Exhibit 2.3(d) and
the Quality Agreement.

11

--------------------------------------------------------------------------------

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

2.4    Promotional Materials. Distributor will not use any Promotional Materials
(as defined below) in connection with the Marketing, sale or distribution of the
Product without Manufacturer’s prior written approval. Distributor may [***].
For purposes of this Agreement, “Promotional Materials” includes all labeling,
advertising and reminder materials (including trade show graphics) as defined in
21 CFR Section 200.200 and Section 202.1(e)(2), as well as any other applicable
provisions of the Act or applicable laws, rules or regulations. For the
avoidance of doubt, [***] or as otherwise required by applicable law; provided,
however, that [***].
2.5    Sampling. Distributor shall not provide any samples of the Products to
any Third Party.
2.6    Rebate Processing.
(a)    [***] will be solely responsible for all federal, state and local
government and private purchasing, pricing or reimbursement programs with
respect to the Product, including taking all necessary and proper steps to
execute agreements and file other appropriate reports and other documents with
governmental and private entities and [***] shall provide reasonable assistance
to [***] to effectuate same. [***] will be solely responsible for payment and
processing of all rebates, and for providing pricing and price disclosures,
whether required by contract or local, state or federal law, for the Product
sold by Distributor.
(b)    Manufacturer is required to refer to Product sales made by Distributor in
Manufacturer’s government price reports. As such, Distributor will provide
Manufacturer with aggregate sales figures for Product sales made by Distributor
and the related Net Sales by product NDC#. The foregoing requirement shall be
satisfied by Distributor providing the monthly reports contemplated by Section
3.5(a)(ii). Manufacturer shall use any data or information relating to pricing
that Distributor provides under this Section 2.6 or otherwise for the limited
purpose of complying with legal price reporting requirements and for no other
purpose. Manufacturer shall not use any such data or information in connection
with its sales, Marketing or contract operations and hereby represents and
warrants to Distributor that such data and information will not be disclosed
among Manufacturer’s personnel for any purpose other than for government price
reporting.

12

--------------------------------------------------------------------------------

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

2.7    Manufacturer’s Reservation of Rights. Except as expressly provided in
this Agreement, nothing contained in this Agreement shall grant (or be construed
as granting) to Distributor any right, title or interest in, to, or under AMAG’s
NDA or any other NDA held in the name of Manufacturer or its Affiliates, or any
supplement thereto, or any intellectual property right owned or controlled by
Manufacturer or its Affiliates. Manufacturer is not granting to Distributor any
right, title or interest, whether express or implied, under any intellectual
property right or other right that Manufacturer or its Affiliates may own or
otherwise control. Nothing contained in this Agreement is intended to limit or
restrict Manufacturer’s ability to manufacture, use, license, Market, or
otherwise exploit the Branded Product. Manufacturer shall be permitted in its
sole discretion to Market the Branded Product itself or through an Affiliate and
to grant Third Parties the right to Market the Branded Product and to supply
Branded Product to those Third Parties during the Term. Following the Term (but,
for clarity, not during the Term), Manufacturer shall be permitted in its sole
discretion to Market the AG Product itself or through an Affiliate and to grant
Third Parties the right to Market the AG Product and to supply AG Product to
those Third Parties.
2.8    Limitation on a Competing Product. During the Term, except with respect
to the Product pursuant to this Agreement or any other product supplied by
Manufacturer or its Affiliates to Distributor or its Affiliates, [***].
2.9    Management. Distributor and Manufacturer shall establish an Executive
Committee with [***] to discuss important issues related to this Agreement,
[***].
ARTICLE 3
FINANCIAL PROVISIONS
3.1    Supply Price. Following the Commencement Date, and during the remaining
Term, Distributor shall pay Manufacturer the Supply Price for the Product.
3.2    Invoice Supply Price.
(a)    The current Manufacturing Costs for each SKU is set forth in Exhibit
1.49, and each such price shall be subject to adjustment in accordance with
Section 3.2(b) [***].
(b)    If the Manufacturing Costs have increased or decreased during any
calendar year (for example, but without limitation, as a result of a change in
cost of manufacturing process or a decrease in volume [***]), or Manufacturer
provides documentation of an increase or decrease in Manufacturing Costs during
the coming calendar year, Manufacturer shall give Distributor prior written
notice of the change, [***].

13

--------------------------------------------------------------------------------

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

3.3    Payment of Invoice Supply Price. Manufacturer shall invoice Distributor
for the Invoice Supply Price together with, or promptly after, each shipment of
Product to Distributor. Distributor shall pay Manufacturer’s invoices: (A)
[***], and (B) within [***] from the date of invoice for shipments of such
Product thereafter. [***].
3.4    Remaining Supply Price.
(a)    Following the first Commencement Date, and during the remaining Term,
Distributor shall pay Manufacturer an amount [***] (the “Remaining Supply
Price”) and shall make such payments in accordance with Section 3.5. For
purposes hereof, a “quarter” is measured as follows with respect to each SKU of
the Products that has a different date of First Commercial Sale: (i) for the
first quarter, the stub period beginning on the date of the First Commercial
Sale and ending on the last day of the Calendar Quarter (March 31, June 30,
September 30, or December 31) in which the First Commercial Sale occurs; (ii)
for the next succeeding quarters, the full Calendar Quarter period; and (iii)
for the final quarter, the stub period beginning on the first day of the
Calendar Quarter and ending on the termination or expiration of this Agreement
in its entirety or with respect to a particular SKU of the Products.
Notwithstanding the foregoing, if the First Commercial Sale occurs on a date
that makes the first stub period less than two months, then for purposes of this
Agreement, the “first quarter” shall be the period beginning on the date of the
First Commercial Sale and ending on the last day of the first full Calendar
Quarter after the stub period.
(b)    The Parties acknowledge that [***]. Accordingly, on an ongoing basis,
Distributor shall revise accrual estimates based on actual amounts or updated
information, compare those revised accrual estimates to existing accruals, and
adjust accruals accordingly. Within [***] after the end of each Calendar
Quarter, Distributor shall provide to Manufacturer (in accordance with the
Accrual Rollforward Report included in Exhibit 3.4(b)) a rollforward of accrual
activity during the previous Calendar Quarter, provided that no accrual shall be
adjusted more than [***] after it was originally reported. Such rollforward
shall show accruals at the beginning of the period, additions to accruals,
actual charges against such accruals, any adjustments to accruals deemed
necessary by Distributor, and ending accruals held by Distributor at the end of
the Calendar Quarter. Any adjustments, both additions to and reductions from the
existing accruals, shall be included in the computation of Net Sales or Net
Distributable Profits (as applicable) for the same Calendar Quarter.

14

--------------------------------------------------------------------------------

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

(c)    Upon the expiration or termination of this Agreement, Distributor shall
continue to provide Manufacturer with an Accrual Rollforward Report as provided
above until all adjustments to existing accruals are determined, provided that
the final Accrual Rollforward Report shall be provided no later than the earlier
of (i) [***] after the last expiry date of the Product sold by Distributor, or
(ii) [***] after the last date Product is sold by Distributor, or such sooner
time as all accruals have been resolved with actual information. Within [***]
after Distributor delivers each such Accrual Rollforward Report, (i) if
Distributor reports a decrease in amounts previously accrued, Distributor shall
pay Manufacturer the resulting increase in the Remaining Supply Price, and (ii)
if Distributor reports an increase in amounts previously accrued, Manufacturer
shall pay Distributor the resulting decrease in the Remaining Supply Price.
Nothing contained herein shall require Manufacturer to pay any disputed amounts
set forth in such report or notice, or otherwise constitute a waiver of any
right of Manufacturer to dispute the amounts set forth in such report or notice.
3.5    Payment of Remaining Supply Price. During the period commencing after the
First Commercial Sale of a Product and continuing thereafter until the end of
the Calendar Quarter following the Calendar Quarter in which this Agreement
terminates or expires (or such longer period as Distributor may be entitled to
sell inventory pursuant to Sections 10.7 and 10.9(a)):
(a)    Within [***] after the end of each calendar month, following the first
delivery of Product or Bailment Product to Distributor, Distributor shall
deliver to Manufacturer a written report, showing with respect to the
immediately preceding month (i) inventory of Product or Bailment Product, as
applicable, on a SKU-by-SKU basis in Distributor’s distribution facilities as of
the first and last days of such month, and units of Product or Bailment Product,
as applicable, received and shipped during such month and as projected months of
supply inventory (all in accordance with the report included in Exhibit
3.5(a)(i)), and (ii) an estimated calculation of the Net Sales, Net
Distributable Profits, and the Remaining Supply Price made in accordance with
the Quarterly Report included in Exhibit 3.5(a)(ii). As Products are sold, the
inventory included on the Quarterly Report shall reflect the inventory with the
oldest dating.
(b)    Within [***] after the end of each Calendar Quarter, Distributor shall
submit to Manufacturer a written report setting forth its reasonable good faith
estimates of the items set forth in Section 3.5(c) in order to allow
Manufacturer to comply with internal reporting obligations.
(c)    Within [***] after the end of each Calendar Quarter, Distributor shall
submit to Manufacturer a Quarterly Report in the form of Exhibit 3.5(a)(ii),
completed with respect to the prior Calendar Quarter. Simultaneously with the
delivery of such written report, Distributor shall remit the total amount due to
Manufacturer for the Remaining Supply Price for such Calendar Quarter.
(d)    Manufacturer may dispute any amounts reflected on a Quarterly Report or
Accrual Rollforward Report, [***]. Manufacturer shall notify Distributor in
writing of each disputed item, specifying the amount thereof in dispute and
setting forth, in reasonable detail, the basis for such dispute, within [***]

15

--------------------------------------------------------------------------------

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

of Distributor’s delivery of the Quarterly Report or Accrual Rollforward Report,
as applicable. In the event of such a dispute, Manufacturer and Distributor
shall attempt to reconcile their differences. If Manufacturer and Distributor
are unable to resolve any such dispute within [***].
3.6    Taxes and Withholding; Brand Fee.
(a)    Except as set forth in Section 3.6(b), Distributor shall make all
payments to Manufacturer under this Agreement without any deduction or
withholding for, or on account of, any tax.
(b)    This Section sets forth the understanding and intentions of Manufacturer
and Distributor relating to the treatment of the Brand Fee, if any. [***]. The
Parties further acknowledge that the reimbursed portion of the Brand Fee, if
any, will be accounted for consistent with the "cost reimbursement doctrine,"
generally recognized by the courts and the Internal Revenue Service, under which
expenditures subject to a right to reimbursement at the time incurred are
reported net of the reimbursement. In furtherance of the intent of the parties,
Manufacturer and Distributor agree to and acknowledge the following:
[***].
3.7    Payments. All amounts hereunder, including, without limitation, the
Invoice Supply Price and the Remaining Supply Price to Manufacturer hereunder
shall be (i) expressed and paid in U.S. dollars, and (ii) made by wire transfer
to the credit of such bank account as shall

16

--------------------------------------------------------------------------------

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

be designated in advance by Manufacturer through written instructions signed by
the Manufacturer.
3.8    Maintenance of Records; Audit. Each Party shall maintain, and shall
direct its Affiliates to maintain, complete, and accurate books and records in
connection with, as applicable, its Manufacture, purchase, handling, Marketing,
sale, distribution, return, and destruction of all Product hereunder, as
necessary to allow the accurate calculation consistent with GAAP of the amounts
due from Distributor to Manufacturer (including the Manufacturing Cost, Invoice
Supply Price, Remaining Supply Price and all items used in the calculation
thereof), the reporting obligations set forth herein, and compliance with the
terms of this Agreement. Each Party shall maintain such books and records for a
period of at least [***] after the end of the calendar year in which they were
generated, or for such longer period as may be required by law, rule, or
regulation. [***] per calendar year and with respect to any additional audit as
provided in Sections 3.5(d) and 5.2(d), each Party shall have the right upon
reasonable notice and at a time mutually agreed by the Parties, [***], to engage
an independent accounting firm [***] to examine in confidence the relevant books
and records of the other Party as may be reasonably necessary to determine or
verify, as applicable, the amounts due from Distributor to Manufacturer
(including the Manufacturing Cost, Invoice Supply Price, Remaining Supply Price
and all items used in the calculation thereof, including any Failure to Supply
Charges under Section 5.2(c)), the financial reporting obligations of the other
Party contemplated herein, and compliance by the other Party with its financial
obligations hereunder. The Party whose books and records are being examined
shall make such books and records available, during normal business hours at the
facility(ies) where such books and records are maintained. Each such examination
shall be limited to pertinent books and records for any year ending not more
than [***] before the date of request, provided that neither Party shall be
permitted to audit the same period of time more than once. Before permitting
such independent accounting firm to have access to such books and records, the
Party being examined may require such independent accounting firm and its
personnel involved in such audit to sign a confidentiality agreement [***] as to
any Confidential Information which is to be provided to such accounting firm or
to which such accounting firm will have access while conducting the audit under
this Section. The independent accounting firm will prepare and provide to each
Party a written report stating whether the reports submitted by the Parties, as
applicable, and amounts paid are correct or incorrect and the amounts of any
discrepancies. In the event either Party’s auditors believe there is a
discrepancy in the calculation of the amounts due from Distributor to
Manufacturer (including the Manufacturing Cost, Invoice Supply Price, Remaining
Supply Price and all items used in the calculation thereof, including any
Failure to Supply Charges under Section 5.2(c)), that Party’s auditors shall be
entitled to take copies or extracts from such records, books of account,
information and data during any review or audit. [***]. If there was an
underpayment by Distributor hereunder, unless disputed by Distributor in
accordance with Section 12.15, Distributor shall promptly (but in no event later
than [***] after its receipt of the independent auditor’s report so concluding)
make payment to Manufacturer of any shortfall by wire transfer in U.S. dollars.
If there was an overpayment by Distributor hereunder, unless disputed by
Manufacturer in accordance with Section 12.15, Manufacturer shall promptly (but
in no event later than [***] after Manufacturer’s

17

--------------------------------------------------------------------------------

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

receipt of the independent auditor’s report so concluding) refund to Distributor
the excess amount by wire transfer in U.S. dollars. In the event of any
underpayment by Distributor or over charge of the Invoice Supply Price by
Manufacturer resulting in a cumulative discrepancy during any calendar year in
excess of the greater of [***].
3.9    Interest on Late Payments. If any undisputed payment under this Agreement
is late, interest shall accrue on the past due amount at a rate equal to the
lesser of (a) [***], and (b) the maximum rate permitted by law.

ARTICLE 4
REGULATORY; COOPERATION
4.1    Regulatory Filings; Communications with a Regulatory Agency.
(a)    Manufacturer will have control over, and authority and responsibility
for, monitoring and coordinating all maintenance of, regulatory actions with
respect to, and communications and filings with and submissions to, FDA or any
regulatory agency with respect to Makena and the Manufacturing, supply,
distribution and sale of the Product under this Agreement
(b)    Manufacturer will have control over, and authority and responsibility
for, monitoring, coordinating, and making all filings with FDA required for
Product Listing for the Product, as well as reporting of Adverse Drug
Experiences and Adverse Events. Manufacturer shall use Commercially Reasonable
Efforts to make such filings with applicable regulatory agencies as necessary
for Manufacturer to carry out its obligations under this Agreement. In the case
of the Product Listing, Distributor shall reasonably assist Manufacturer in
preparing the required form for filing by Manufacturer. Manufacturer represents
and warrants to Distributor that it will timely file with FDA a Product Listing
form showing Distributor as the distributor of the Product.
(c)    Distributor shall be solely responsible for communications and filings
with and submissions to any regulatory agency or other federal, state or local
governmental authority concerning Product sales, prices, discounts, rebates,
fees, charge-backs, and other payments associated with Distributor’s Marketing,
distribution and sale of Product under this Agreement, including, without
limitation, all reporting, and disclosure obligations under the Medicaid Drug
Rebate Program (e.g., Monthly and Quarterly Average Manufacturer Price, Baseline
Average Manufacturer Price, and Rebate Per Unit), Medicare Part B (Quarterly
Average Sales Price), the Veteran’s HealthCare Act 602 (Public Health Service
340B Quarterly Ceiling Price), the Veteran’s HealthCare Act 603 (Quarterly and
Annual Non-Federal Average Manufacturer Price and Federal Ceiling Price), Best
Price, Federal Supply Schedule Contract Prices and Tricare Retail Pharmacy
Refunds and Medicare Part D. Distributor shall also cooperate fully with
Manufacturer and shall supply all data and information reasonably requested by
Manufacturer

18

--------------------------------------------------------------------------------

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

within [***] (or such other amount of time as mutually agreed or proscribed by
such federal, state or local governmental authority or governmental requirement)
to enable Manufacturer to comply with any applicable federal, state or local
reporting and disclosure requirements concerning Manufacturer’s supply of
Product to Distributor under this Agreement.
(d)    Concurrent with the execution and delivery of this Agreement,
Manufacturer shall provide to Distributor information regarding the [***] for
the first full quarter following launch of the Branded Product (and the date of
such first full quarter), which may be used by Distributor solely in connection
with Distributor’s government reporting obligations relating to the Product. In
addition, upon request by Distributor, Manufacturer shall provide any other
information reasonably requested by Distributor to enable Distributor to comply
with any Applicable Laws concerning Distributor’s marketing and distribution of
the Product in accordance with this Agreement.
4.2    Distributor’s Communications with FDA or a Governmental Agency. If
Distributor reasonably concludes that it is necessary or advisable for
Distributor to communicate with FDA or a regulatory agency regarding
Distributor’s activities under this Agreement, then before such communication
Distributor shall (to the extent practicable) so advise Manufacturer and, if
applicable, provide Manufacturer with copies of all proposed correspondence
between Distributor and the applicable entity. Distributor shall provide
Manufacturer with copies of all correspondence, documents and materials received
from or provided to FDA or a regulatory agency concerning the Product or any
activities under this Agreement at least [***] after receipt or before the
submission of such correspondence, documents, or materials (unless a shorter
period is required in the reasonable discretion of Distributor due to applicable
law or a requirement of FDA or a regulatory agency). Manufacturer shall promptly
respond to Distributor regarding any such proposed correspondence or
communications; provided that, in the event Distributor has used Commercially
Reasonable Efforts to confirm Manufacturer’s receipt of such correspondence and
Manufacturer does not respond within [***] of receipt of such correspondence,
Manufacturer shall be deemed to have approved such correspondence or
communications in the form presented to Manufacturer. Distributor shall consult
with Manufacturer and adopt all reasonable suggestions and recommendations of
Manufacturer concerning any meeting or written or oral communication with FDA or
a regulatory agency.
4.3    Cooperation. Each Party shall provide the other with all reasonable
assistance and take all actions reasonably needed to enable such other Party to
comply with any law, rule or regulation applicable to such other Party’s
activities under this Agreement. Except as otherwise provided in Article 7, such
assistance and actions shall include, without limitation, informing the other
Party within [***] of receiving any information that:
(a)    raises any material concerns regarding the safety or efficacy of any
Product;
(b)    is reasonably likely to lead to a recall or market withdrawal of or other
corrective action with respect to the Product in the Territory; or

19

--------------------------------------------------------------------------------

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

(c)    concerns any investigation, inspection, detention, seizure or injunction
involving any Product by any governmental entity or regulatory agency in the
Territory.
Manufacturer and Distributor shall, in each such case, adhere to the executed
Quality Agreement requirements to jointly determine whether subsequent
notification to any government entity or regulatory agency is required, and
[***]. Notwithstanding anything in this Agreement to the contrary, Manufacturer
shall not be obligated to supply Distributor with the Products until the Quality
Agreement is executed by the Parties. [***]. Furthermore, each Party shall
inform the other Party within [***] and provide such other Party with all
reasonable assistance after receiving any information that indicates or suggests
a potential material liability for either Party to Third Parties arising from or
in connection with the Product.
ARTICLE 5
SUPPLY, ORDERING, AND FORECASTS
5.1    Forecasts; Purchase Orders; Launch Quantities.
(a)    Within [***] of the Effective Date (or such later date as the Parties may
mutually agree) and within the first [***] of each calendar month following the
First Commercial Sale, Distributor shall provide to Manufacturer a non-binding
(subject to Section 5.1(c)), good faith written estimate (each a “Rolling
Forecast”) by month of Distributor’s reasonably anticipated quantity
requirements for Product by SKU. Distributor’s first Rolling Forecast for each
SKU of the Products shall cover the [***] period starting with the calendar
month following the month in which the First Commercial Sale shall occur for
such SKU, and each subsequent Rolling Forecast shall cover the [***] period
starting with the calendar month following the month in which Distributor
provides such Rolling Forecast to Manufacturer. For example, [***]. Within [***]
of receipt of the Rolling Forecast, Manufacturer shall confirm to Distributor in
writing Manufacturer’s acceptance of the Rolling Forecast. If within such [***]
period Manufacturer notifies Distributor of a problem with the Rolling Forecast,
including a reasonable determination that (i) the quantities of Product in the
Rolling Forecast, or any month(s) therein, exceeds the amount necessary for
Distributor to meet demand for the Product, (ii) Manufacturer cannot supply the
full quantities of Product in the Rolling Forecast, or (iii) if the Rolling
Forecast does not comply with the requirements of Sections 5.1(d) or 5.1(f), the
Parties shall cooperate in resolving such problems relating to the supply of
Products under this Agreement.
(b)    Within [***] of the Effective Date, Distributor shall submit binding
purchase orders to Manufacturer for the quantities of Product sufficient to meet
demand during the [***] of the first Rolling Forecast (the “Launch Quantities”).
Manufacturer shall use Commercially Reasonable Efforts to deliver the quantities
specified on Exhibit 5.1(b) hereto (which will be the quantities specified in
the first month of the

20

--------------------------------------------------------------------------------

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

Rolling Forecast) as Bailment Product (the “Initial Launch Quantities”) on or
before the Commencement Date. In the event that the launch scenario is different
from the assumptions identified on Exhibit 5.1(b) (e.g., fewer competitors
launch a Competing Product) as of the Commencement Date, the Parties shall
discuss in good faith revisions to the Initial Launch Quantities and/or Rolling
Forecast in light of such circumstances.
(c)    Accompanying each Rolling Forecast, Distributor shall place monthly
purchase orders (each a “Firm Order”) for Product for [***] period of each
Rolling Forecast being the “Firm Order Period”) by written or electronic
purchase order to Manufacturer (or by any other means agreed to by the Parties).
Each purchase order shall specify the quantity and type of each Product to be
delivered and the desired delivery dates in the applicable month (the “Firm
Order Quantity”). The purchase orders submitted by Distributor, or required to
be submitted by Distributor hereunder, shall represent a binding obligation upon
Distributor and may not be cancelled or adjusted in any manner expect by written
consent of Manufacturer. Manufacturer shall acknowledge Distributor's purchase
order(s) within [***] of Manufacturer’s receipt of the purchase order(s). Within
[***] of receipt of the purchase order for the Firm Order Period, Manufacturer
shall confirm to Distributor in writing Manufacturer’s acceptance of the Firm
Order Quantity or its modification of the Firm Order Quantity pursuant to the
following provisions. If the Firm Order does not comply with the order
limitations in Section 5.1(d), Manufacturer may modify, [***], the quantity of
Product to be supplied to Distributor (a “Modified Firm Order Quantity”) and
shall provide notification of such to Distributor. Upon acceptance by
Manufacturer, an accepted Firm Order Quantity or Modified Firm Order Quantity is
binding upon Manufacturer such that Manufacturer shall use Commercially
Reasonable Efforts to timely deliver to Distributor such quantity of Product.
(d)    The Rolling Forecasts and purchase orders for Firm Order Periods shall
comply with the increments and minimum order quantities for the Products set
forth on Exhibit 5.1(d) hereto, which may be amended by written notice from
Manufacturer from time to time. [***].
(e)    Distributor shall be required to purchase at a minimum [***], except that
if (i) (A) the Commencement Date does not occur within six (6) months of the
Effective Date, (B) [***], or (C) [***], and, in any such case, Distributor
reasonably determines that such circumstances have reduced the potential market
share of the Product and that as a result Distributor’s Rolling Forecast for
Launch Quantities are likely to exceed the demand of Distributor’s customers for
such Launch Quantities or (ii) there is a Supply Interruption and Distributor
reasonably determines that the failure has reduced or is reasonably likely to
reduce

21

--------------------------------------------------------------------------------

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

the demand of Distributor’s customers for the Product, then in each case,
Distributor may by written notice to Manufacturer, as promptly as practical and,
in any event, within [***] after Distributor’s determination under clause (i) or
Manufacturer’s failure and Distributor’s reasonable determination under clause
(ii), reduce Distributor’s binding commitments under purchase orders then in
effect to reflect such actual or expected reduction in demand, and Distributor
may also reduce future Rolling Forecasts to reflect such actual or expected
reduction in demand.
(f)    Manufacturer shall not be required to accept any Rolling Forecast for
Products in which (i) there is any change to any month in the Firm Order Period,
(ii) there is a change (increasing or decreasing) of more than [***] in any
month for the [***], in each case in quantity of units of Products contained in
the immediately preceding Rolling Forecast. [***].
(g)    Manufacturer shall use its [***].
(h)    [***].
5.2    Delivery; Delays; Supply Interruption.
(a)    Any shipment delivered that is within plus or minus [***] of the quantity
ordered will be considered as meeting such order quantity, and any shipment
delivered on a date within [***] of the delivery date specified on the purchase
order will be considered as delivered on time. In the event any delivery is less
than [***] of an [***], as applicable, Manufacturer shall be deemed as meeting
such order quantity if, as of the delivery date specified in the purchase order,
Distributor has sufficient inventory of the Product to cover the shortfall
(measured by the difference between the actual delivery amount and [***] of an
accepted Firm Order Quantity or Modified Firm Order Quantity, as applicable) in
the quantity delivered.
(b)    In the event that any Product supply will be delayed, in whole or in
part, more than [***], Manufacturer will notify Distributor of such late supply
as soon as possible and promptly thereafter agree with Distributor, such
agreement not to be unreasonably withheld, on a later date for supply that is
intended to accommodate the delay, taking into consideration Manufacturing and
product availability constraints outside of Manufacturer’s

22

--------------------------------------------------------------------------------

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

reasonable control. In no event shall a delivery delay alter Manufacturer’s
obligation to supply the amount of Product subject to a purchase order issued by
Distributor and accepted by Manufacturer for the Firm Order Period.
(c)    In the event that Manufacturer fails (except due to a Force Majeure
Event) with respect to either (i) [***] to deliver at least [***] of each of the
Firm Order Quantities or Modified Firm Order Quantities for such periods [***]
within [***] of the applicable delivery date, or (ii) with respect to [***] to
deliver at least [***] of the Firm Order Quantity or Modified Firm Order
Quantity for such period within [***] of the delivery date (either being a
“Supply Interruption”), and as a direct result of such Supply Interruption
Distributor incurs any Failure to Supply Charges, [***]. A Supply Interruption
shall be deemed resolved when Manufacturer has either filled all delinquent
purchase orders from Distributor or delivered enough Product to enable
Distributor to supply all unfilled customer orders and satisfy Distributor’s
minimum Safety Stock requirements.
During the Term and subject to the performance by Manufacturer of its
obligations to supply the Product, Distributor shall use [***] to maintain no
less than [***] safety stock inventory, which safety stock level shall be
measured as the forecasted daily inventory level at the time of the Supply
Interruption. During a Supply Interruption and during any period before a Supply
Interruption is anticipated to occur, Distributor shall [***]. In addition, and
notwithstanding anything in this Agreement to the contrary, to the extent that
Distributor fails to [***].

23

--------------------------------------------------------------------------------

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

Failure to Supply Charges subject to reimbursement under this Section [***].
(d)    Distributor shall provide to Manufacturer a report calculating any
Failure to Supply Charges, which shall include [***] before [***]. Manufacturer
may dispute any amounts reflected on a Failure to Supply Charges report, but
only on the basis that the amounts were not correctly calculated. Manufacturer
shall notify Distributor in writing of each disputed item, specifying the amount
thereof in dispute and setting forth, in reasonable detail, the basis for such
dispute, within [***] of receipt of the documentation specified in this Section
5.2(d). In the event of such a dispute, Manufacturer and Distributor shall
attempt to reconcile their differences. If Manufacturer and Distributor are
unable to resolve any such dispute within [***] after Manufacturer’s delivery of
its notice of dispute to Distributor, [***].
ARTICLE 6
DELIVERY TERMS
6.1    Delivery Terms; Title Passage.
(a)    Except with respect to Bailment Product, (i) Manufacturer shall deliver
all quantities of Products to Distributor [***] Manufacturer’s or its
subcontractor’s manufacturing facility, warehouse or such other facility
mutually agreed to by the Parties, (ii) [***], and (iii) Distributor shall be
responsible for all freight, insurance, handling, fees, taxes and other costs
associated with the shipment of Products, as well as all export licenses, import
licenses and customs formalities for the import and export of goods.

24

--------------------------------------------------------------------------------

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

(b)    From time to time prior to the Commencement Date for each SKU,
Manufacturer may ship Distributor quantities of such SKU under bailment (the
“Bailment Product”) on the terms of the Bailment Agreement between the Parties
dated as of the date of this Agreement (the “Bailment Agreement”). The Bailment
Agreement shall govern the terms of shipment, freight and insurance costs,
title, and risk of loss of Products shipped to Distributor’s warehouse pursuant
to the Bailment Agreement. [***].
6.2    Packaging & Labeling. All Product supplied to Distributor hereunder shall
be in finished packaged form which complies with AMAG’s NDA and all applicable
law, including future requirements of the Drug Supply Chain Security Act at the
time of delivery of Products to Distributor. Manufacturer shall, [***] produce
all Packaging and Labeling materials to be used for the Product (including
print-ready artwork with Distributor’s NDC#). Upon completion of the design for
the Packaging and Labeling, Manufacturer shall provide Distributor with a sample
for Distributor’s approval. Any changes to the Packaging and Labeling
specifications requested by Distributor shall require the prior written consent
of Manufacturer, which shall not be unreasonably withheld, conditioned or
delayed. If Manufacturer consents to such changes, [***]. Distributor shall
clearly identify that the Product is manufactured for Manufacturer on all
packaging materials unless otherwise requested by Manufacturer.
6.3    Shipping Documentation. Each delivery of Product shall be accompanied by
a packing slip that describes the Product and shows Distributor’s purchase order
number for the Product being delivered. Manufacturer shall supply with each
delivery all documentation required by the Quality Agreement including, but not
limited to, a certificate of compliance for each lot of the Product included in
the delivery.
6.4    Governing Terms. To the extent there is any conflict or inconsistency
between this Agreement, the Bailment Agreement and any purchase order, purchase
order release or any similar business document, the terms of this Agreement
shall govern and control. Any other document which shall conflict with or be in
addition to the terms and conditions of this Agreement is hereby rejected
(unless the Parties shall have mutually agreed to the contrary in writing in
respect of a particular instance). Notwithstanding the foregoing, in the event
of any conflicts between this Agreement and the Quality Agreement regarding
quality-related activities, the Quality Agreement shall govern and control.
6.5    Marketing Costs. Except as expressly set forth in this Agreement, [***]
shall be solely responsible for all costs and expenses related to the Marketing,
sale and distribution of Product in the Territory.
6.6    Acceptance and Rejection and Product Defects.
(a)    Defective Product Claims Generally. Delivery of any Product by
Manufacturer to Distributor shall constitute a certification by Manufacturer
that such Product conforms to the representations and warranties made by
Manufacturer in this Agreement.

25

--------------------------------------------------------------------------------

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

Distributor shall (i) have [***] after receipt of each delivery of Product to
determine if such Product conforms to such warranties and to accept or reject
any of such Product that fails to conform to such warranties, (ii) submit any
claims for failure to so conform (“Product Claims”) in writing to Manufacturer
within such [***] period describing in reasonable detail the nonconforming
characteristics of the Product, and (iii) be deemed to have accepted any Product
if it fails to submit a Product Claim during such [***] period.
(b)    Disputed Defective Product Claims. If Distributor submits a Product Claim
and Manufacturer notifies Distributor in writing that Manufacturer does not
agree with the Product Claim within [***] after it receives the Product Claim,
the Parties shall submit the Product in question to a [***] independent Third
Party that has the capability of testing the Product to determine whether the
Product complies with the warranties in Section 6.7(a), which independent Third
Party will make such determination within [***] after submission of the Product
thereto by the Parties. The determination of such independent party shall be
binding on the Parties. [***].
(c)    Remedies for Defective Products. If Manufacturer agrees with the Product
Claim, then Manufacturer shall (a) instruct Distributor whether to return or
destroy the Product in question, and (b) at Manufacturer’s option either (i)
credit Distributor the Supply Price for the Product in question as promptly as
possible (but in any event within [***]), or (ii) provide Distributor with
replacement Product as promptly as possible using Commercially Reasonable
Efforts as agreed by the Parties, but in any event within [***] after
Distributor submitted its Product Claim to Manufacturer pursuant to Section
6.6(a) or (y) in the event Manufacturer disputes a Product Claim, [***] after
the Parties resolved such dispute pursuant to Section 6.6(b). [***].
6.7    Product Warranty.
(a)    Warranty Generally; Minimum Dating. Manufacturer warrants that (x) upon
delivery to Distributor’s warehouse under the Bailment Agreement of all Bailment
Product supplied to Distributor pursuant to the Bailment Agreement, and (y) upon
delivery at the shipping point of all other Products supplied to Distributor in
accordance with Section 6.1(a), upon delivery by Manufacturer, all Product
Manufactured and/or supplied to Distributor (i) shall comply with the
Specifications, this Agreement and the Quality Agreement, (ii) shall have been
manufactured in compliance with all applicable laws, rules and regulations,
including without limitation, cGMP requirements, (iii) shall not be adulterated
or misbranded within the meaning of the Act, and (iv) may be introduced into
interstate commerce pursuant to the Act. All Product Manufactured and/or
supplied by Manufacturer shall, upon receipt by Distributor or its designee,
have dating of not less than [***] of shelf-life for such Product, except that
Bailment Product and Initial Launch Quantities shall have dating of not less
than [***]

26

--------------------------------------------------------------------------------

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

prior to expiration as of the date title to such Bailment Product transfers to
Distributor under the Bailment Agreement. Supply of any Product having shorter
dating shall be subject to the written consent of Distributor, which shall not
be unreasonably withheld.
(b)    Warranty Exceptions. Warranty claims shall not apply to damaged or
non-conforming Product to the extent such damage or non-conformity is caused by
Distributor’s negligence, handling or storage that is not in accordance with the
Specifications, cGMP or FDA approved Product Labeling, or failure to comply with
its obligations under Section 2.3.
6.8    [***].
ARTICLE 7
PHARMACOVIGILANCE; RECALLS
7.1    Pharmacovigilance. Manufacturer shall be solely responsible for
maintaining the safety database for Products and for the pharmacovigilance
surveillance and timely reporting of all relevant adverse drug reactions and
experiences, Product quality, Product complaints and safety data relating to the
Compound, Products, and Makena to the appropriate regulatory authorities in the
Territory. Distributor shall cooperate with Manufacturer in fulfilling those
responsibilities in accordance with the terms of the Pharmacovigilance
Agreement. Notwithstanding anything in this Agreement to the contrary,
Distributor shall not be permitted to Market the Products until the
Pharmacovigilance Agreement is executed by the Parties. Except as required by
applicable laws, rules, or regulations, Distributor shall not disclose any
information concerning any adverse drug reactions or experiences or any
complaint concerning any Product to any Third Party without the prior written
consent of Manufacturer.
7.2    Recalls.
(a)    FDA Required Recall. If a recall of any Product sold by or on behalf of
Distributor is required or recommended by FDA, or if a recall, suspension or
other withdrawal of any Product sold by or on behalf of Distributor is deemed
advisable by Manufacturer, such recall, suspension or withdrawal shall be
implemented and administered by the Parties in a manner that is appropriate and
reasonable under the circumstances and in conformity with accepted trade
practices and any requests, recommendations, or orders of FDA. Each Party shall
cooperate with the other Party to effectuate such recall, suspension or other
withdrawal as specified in the Quality Agreement and all field alerts shall be
the responsibility of Manufacturer. As soon as reasonably practicable, but in no
event more than [***] after the decision to implement a recall, Distributor
shall provide Manufacturer all information in Distributor’s possession or
control reasonably necessary for Manufacturer to comply with FDA reporting
requirements.
(b)    Discretionary Recall. In the absence of an order or recommendation of
FDA, if the Parties are unable to agree upon a Product recall, suspension or
other withdrawal (other than the determination of who shall bear the costs of
such event), [***] shall make

27

--------------------------------------------------------------------------------

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

the final decision on all matters related to the recall, suspension or other
withdrawal (including matters relating to the method of implementation), except
that [***] may implement and administer a recall, suspension or withdrawal of
Product distributed by it if it reasonably believes, based on the advice of
outside regulatory counsel and after good faith discussion with [***], that a
failure to administer a recall, suspension or withdrawal would pose health or
safety risks to the public.
(c)    Recall Costs and Expenses. [***] shall pay all Recall Costs and Expenses
in connection with a recall, suspension or withdrawal under this Section 7.2,
except that [***] shall bear such Recall Costs and Expenses to the extent such
recall, suspension, or withdrawal is implemented as a result of [***] negligence
or breach of its obligations under this Agreement. As used in this Section 7.2,
the term “Recall Costs and Expenses” means only: [***].
(d)    Distributor shall establish a track and trace and recall system which
will enable Distributor to trace the Products to the first consignee and, to the
extent reasonably possible, to identify, as quickly as possible, customers
within the Territory who have been supplied with Products, and to recall such
Products from such customers.
(e)    Cooperation. Each Party shall cooperate with the other Party to
effectuate any such recall or other withdrawal as specified in the Quality
Agreement.
7.3    Information. As soon as reasonably practicable, but in no event more than
[***] after Manufacturer’s written request, Distributor shall provide
Manufacturer all information in Distributor’s possession or control reasonably
necessary for Manufacturer to comply with FDA reporting requirements. This
Section shall not apply to Adverse Drug Experiences or Safety Information which
shall be governed by Section 7.1.
ARTICLE 8
REPRESENTATIONS AND WARRANTIES
8.1    Manufacturer Representations and Warranties. Manufacturer represents and
warrants to Distributor that, as of the Effective Date:
(a)    it is an entity duly organized, validly existing and in good standing
under the laws of the state or country of its incorporation and has full
corporate power and authority to enter into this Agreement and to carry out the
provisions hereof;
(b)    all necessary corporate and other authorizations, consents and approvals
which are necessary or required for it to enter into this Agreement have been
duly obtained;

28

--------------------------------------------------------------------------------

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

(c)    the entering into of this Agreement by Manufacturer shall not (i) violate
any provision of law, statute, rule or regulation or any ruling, writ,
injunction, order, judgment or decree of any court, administrative agency or
other governmental body to which Manufacturer is subject, or (ii) conflict with
or result in any breach of any of the terms, conditions or provisions of, any
agreement to which Manufacturer or any of its Affiliates is a party or by which
it or its Affiliates or any of its or their properties or assets is bound or
affected;
(d)    the Product will be sold to Distributor free and clear of all liens,
claims and encumbrances of any nature;
(e)    to the best of its knowledge, the manufacture, use and sale of the
Products does not infringe the patents of any Third Party in the Territory;
(f)    it has not granted any license, right or interest in or to the Product,
or any method of manufacture thereof, to any Third Party that would conflict
with the rights being granted to Distributor under this Agreement;
(g)    the facilities where the Product is Manufactured conforms, and shall
continue to conform throughout the Term, in all respects to applicable laws
governing such facilities;
(h)    it will timely file the Label for the Product as a supplement to AMAG’s
NDA; and
(i)    it will maintain a stability testing program in full compliance with
AMAG’s NDA.    
8.2    Distributor Representations and Warranties. Distributor represents and
warrants to Manufacturer as of the Effective Date that:
(a)    it is a limited liability company duly organized, validly existing and in
good standing under the laws of the state or country of its formation and has
full limited liability company power and authority to enter into this Agreement
and to carry out the provisions hereof;
(b)    all necessary corporate and other authorizations, consents and approvals
which are necessary or required for it to enter into this Agreement have been
duly obtained; and
(c)    the entering into of this Agreement by Distributor shall not (i) violate
any provision of law, statute, rule or regulation or any ruling, writ,
injunction, order, judgment or decree of any court, administrative agency or
other governmental body to which Distributor is subject, or (ii) conflict with
or result in any breach of any of the terms, conditions or provisions of, any
agreement to which Distributor or any of its Affiliates is a party or by which
it or its Affiliates or any of its or their properties or assets is bound or
affected.
8.3    Debarment and Exclusion. Each Party represents and warrants that neither
it, nor any of its employees or agents performing hereunder, have ever been, are
currently, or are the subject of a proceeding that could lead to it or such
employees or agents becoming, as applicable, a Debarred Entity or Debarred
Individual, an Excluded Entity or Excluded Individual or a

29

--------------------------------------------------------------------------------

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

Convicted Entity or Convicted Individual. Each Party further covenants,
represents and warrants that if, during the term of this Agreement, it, or any
of its employees or agents performing hereunder, become or are the subject of a
proceeding that could lead to a Person becoming, as applicable, a Debarred
Entity or Debarred Individual, an Excluded Entity or Excluded Individual or a
Convicted Entity or Convicted Individual, the Party in question shall promptly
notify the other Party, and the Parties will promptly discuss necessary measures
to avoid such a circumstance from affecting a Party’s performance hereunder. For
purposes of this provision, the following definitions shall apply:
A “Debarred Individual” is an individual who has been debarred by FDA pursuant
to 21 U.S.C. §335a (a) or (b) from providing services in any capacity to a
Person that has an approved or pending drug or injectable product application.
A “Debarred Entity” is a corporation, partnership or association that has been
debarred by FDA pursuant to 21 U.S.C. §335a (a) or (b) from submitting or
assisting in the submission of any abbreviated drug application, or a subsidiary
or affiliate of a Debarred Entity.
An “Excluded Individual” or “Excluded Entity” is (i) an individual or entity, as
applicable, who has been excluded, debarred, suspended or is otherwise
ineligible to participate in federal health care programs such as Medicare or
Medicaid by the Office of the Inspector General (OIG/HHS) of the U.S. Department
of Health and Human Services, or (ii) is an individual or entity, as applicable,
who has been excluded, debarred, suspended or is otherwise ineligible to
participate in federal procurement and non-procurement programs, including those
produced by the U.S. General Services Administration (GSA).
A “Convicted Individual” or “Convicted Entity” is an individual or entity, as
applicable, who has been convicted of a criminal offense that falls within the
ambit of 21 U.S.C. §335a (a) or 42 U.S.C. §1320a - 7(a), but has not yet been
excluded, debarred, suspended or otherwise declared ineligible.
8.4    Disclaimer of Warranties.
(a)    EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, NEITHER PARTY MAKES ANY
REPRESENTATION OR WARRANTY TO THE OTHER PARTY OF ANY KIND INCLUDING, WITHOUT
LIMITATION, ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR
PURPOSE.
(b)    NEITHER PARTY MAKES ANY WARRANTIES, EXPRESS OR IMPLIED, CONCERNING THE
SUCCESS OF THE COMMERCIAL EXPLOITATION OF THE PRODUCT.
8.5    Limitations of Liabilities.
(a)    [***].

30

--------------------------------------------------------------------------------

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

(b)    The limitation of liability set forth in this Section 8.5 reflects a
deliberate and bargained for allocation of risks between Distributor and
Manufacturer and is intended to be independent of any exclusive remedies
available under this Agreement, including any failure of such remedies to
achieve their essential purpose.
(c)    The Parties acknowledge that the limitations of liability set forth in
this Section 8.5 are an essential element of this Agreement between the Parties
and that the Parties would not have entered into this Agreement without such
limitations of liability.
ARTICLE 9
INDEMNIFICATION
9.1    Indemnification. In order to distribute among the Parties the
responsibility for claims arising out of this Agreement, and except as otherwise
specifically provided for herein, the Parties agree as follows:
(a)    Manufacturer’s Indemnification Obligations. Manufacturer shall defend,
indemnify and hold harmless each of Distributor and its Affiliates and its and
their directors, officers, employees and contractors (“Distributor Party”) from
and against any and all Losses arising from, relating to or in connection with
(i) any Third Party claim, lawsuit, investigation, proceeding, regulatory
action, or other cause of action (“Claim”) resulting from any breach of this
Agreement, negligent acts or negligent omissions to act, or willful misconduct
of any AMAG Party in connection with the performance of its obligations under
this Agreement; (ii) except to the extent subject to indemnification by
Distributor pursuant to Section 9.1(b)(iii), any Claim for personal injury or
property damage based on or arising out of the use, Manufacturing or Marketing
of Makena or the use or Manufacturing of the Product; (iii) Manufacturer’s
failure to Manufacture, store or release Product for shipment in accordance with
applicable laws, regulations, AMAG’s NDA or this Agreement; (iv) the breach by
Manufacturer of any of its representations or warranties contained in this
Agreement; (v) any claim that the Product Label (including the information in
the Makena Label, but excluding the Distributor’s Label information) contains
any false or misleading statements or representations or omits information
necessary to adequately warn consumers of the risks inherent in the Product;
(vi) any governmental investigation or proceeding (administrative or otherwise)
or Third Party claim relating to a potential or actual settlement agreement
between Manufacturer and a Third Party that plans to market or is marketing a
Generic Equivalent Product; or (vii) any misuse by a AMAG Party of Distributor’s
company name or logo or other trademark; except, in each case, to the extent
that the Losses are caused by the negligence, breach of the terms of this
Agreement, or willful misconduct of a Distributor Party. Failure to Supply
Charges shall not be subject to indemnification by Manufacturer under this
Article 9.

31

--------------------------------------------------------------------------------

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

(b)    Distributer’s Indemnification Obligations. Distributor shall defend,
indemnify and hold harmless each of Manufacturer and its Affiliates and its and
their directors, officers, employees and contractors (“AMAG Party”) from and
against any Losses arising from or in connection with: (i) any Claim resulting
from any breach of this Agreement, negligent acts or negligent omissions to act,
or willful misconduct of any Distributor Party in connection with the
performance of its obligations under this Agreement; (ii) any Claim for personal
injury or property damage based on or arising out of the Marketing of the
Product by Manufacturer or the failure of Distributor to store or ship Product
in accordance with applicable laws, regulations or this Agreement, to the extent
that such liability is a result of the acts or failure to act of Distributor,
its Affiliates, or its employees, agents, partners or contractors; (iii) the
breach by Distributor of any of its representations or warranties contained in
this Agreement; or (iv) any misuse by the Distributor Parties of Manufacturer’s
company name or logo or other trademark; except, in each case, to the extent
that the Losses are caused by the negligence, breach of the terms of this
Agreement, or willful misconduct of a AMAG Party.
9.2    Procedures. As soon as a Party becomes aware of the possibility of a
claim involving indemnification hereunder, the indemnified Party shall give the
indemnifying Party prompt written notice in writing and shall permit the
indemnifying Party to have control over the defense of such claim or suit. The
indemnified Party agrees to provide all reasonable information and assistance to
the indemnifying Party in such defense. No such claims shall be settled other
than by the Party defending the same, and then only with the consent of the
other Party, which shall not be unreasonably withheld or delayed; provided,
however, that the indemnified Party shall have no obligation to consent to any
settlement of any such claim which imposes on the indemnified Party any
liability or obligation which cannot be assumed and performed in full by the
indemnifying Party. In the event that a claim for indemnification is brought or
made against both Parties, then each Party will have the right to be represented
by counsel at its own expense.
ARTICLE 10
TERM AND TERMINATION
10.1    Term. This Agreement shall commence as of the Effective Date and shall
continue for a period of [***] after the Commencement Date, unless terminated
earlier as provided below (the “Initial Term”). This Agreement will
automatically renew for additional [***] terms (together with the Initial Term,
the “Term”) unless either Party elects not to renew this Agreement by written
notice to the other Party, which notice must be provided at least [***] prior to
the expiration of the Term.
10.2    Termination of Agreement by Manufacturer.
(a)    Prior to Commencement Date. Manufacturer may terminate this Agreement at
any time prior to the Commencement Date for any reason upon written notice to
Distributor; [***].

32

--------------------------------------------------------------------------------

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

(b)    Convenience. After the [***] period following the First Commercial Sale
of the Product, Manufacturer may terminate this Agreement at any time for any
reason upon [***] written notice to Distributor.
(c)    Distributor Change in Control. If Distributor becomes subject to any
Change in Control, Distributor shall so notify Manufacturer, in writing, within
thirty (30) days. Manufacturer may terminate this Agreement upon [***] written
notice to Distributor after a Change in Control of Distributor, which notice of
termination must be given no later than (i) [***] after Distributor gives
Manufacturer written notice of the Change in Control, or (ii) if notice is not
provided by Distributor, at any time within [***] following Manufacturer
becoming aware of such Change in Control.
10.3    Termination by Non-Defaulting Party upon Event of Default. Upon the
occurrence of an Event of Default, in addition to all rights and remedies
provided by applicable law, the non-defaulting Party in its sole discretion may
terminate this Agreement upon [***] prior written notice to the defaulting
Party. For purposes of this Section 10.3, the occurrence of any one or more of
the following acts, events or occurrences shall constitute an “Event of Default”
under this Agreement: (a) [***]; or (b) either Party fails to cure any material
breach of its obligations under this Agreement, within [***] after written
notice of the breach from the other Party, provided that all financial
obligations hereunder shall be deemed material for purposes of this Section
10.5.
10.4    Termination by Mutual Agreement. In the event that the Parties mutually
determine that the arrangements contemplated by this Agreement are no longer in
the best interests of the Parties or the Parties are not otherwise compatible,
the Parties may at any time, by mutual written agreement, terminate this
Agreement.
10.5    Termination Upon FDA Notice.
(a)    Either Party may terminate this Agreement by written notice to the other
Party if FDA has notified either Party in writing (an “FDA Notice”) that
Distributor’s Marketing, distributing, offering to sell, or selling the Product
which meets the Specifications would constitute a violation of the Act or
applicable regulations thereunder. In the event a Party seeks to trigger this
termination right, the terminating Party shall provide the other Party [***]
written notice of its intention to terminate this Agreement. Upon receipt of the
FDA Notice, Distributor shall cease Marketing, promoting and selling the
Product, and the Parties shall work together in good faith to overcome the basis
of the FDA Notice during such [***] period. This Agreement shall automatically
terminate at the end of such [***] period unless the Parties mutually agree that
issues raised in the FDA Notice have been resolved.
(b)    Either Party may terminate this Agreement immediately upon written notice
to the other Party, if there is a final administrative or judicial decision from
which no appeal has been or can be taken (other than a petition to the United
States Supreme Court for a writ of certiorari) finding that this Agreement
violates applicable law;

33

--------------------------------------------------------------------------------

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

provided that, prior to termination, the Parties shall engage in good faith
discussions to revise the Agreement, if possible, to preserve the basic
commercial terms of the Agreement and comply with applicable law .
10.6    Force Majeure Events. If either Party is prevented from performing any
of its obligations hereunder, except for payment obligations, due to any cause
which is beyond the non-performing Party's (the “Non-performing Party”)
reasonable control, including fire, explosion, flood or other acts of God; acts,
regulations, or laws of any government; war (whether or not declared), civil
commotion or terrorist act; strike or lock-out; or failure of public utilities
(a “Force Majeure Event”), such Non-performing Party shall not be liable for
breach of this Agreement with respect to such non-performance to the extent any
such non-performance is due to a Force Majeure Event. Such non-performance will
be excused to the extent affected by the Force Majeure Event and for as long as
such event shall be continuing, provided that the Non-performing Party gives
immediate written notice to the other Party (the “Performing Party”) of the
Force Majeure Event. Such Non-performing Party shall exercise all Commercially
Reasonable Efforts to eliminate the Force Majeure Event and to resume
performance of its affected obligations as soon as practicable, and the Parties
shall use commercially reasonable efforts to mitigate any damages. Should the
Force Majeure Event continue unabated for a period of [***] or more, the Parties
shall enter into good faith discussions with a view to alleviating its effects
or to agreeing upon such alternative arrangements as may be fair and reasonable
having regard to the circumstances prevailing at that time, and if such
discussions do not result in a new or modified agreement within [***] following
commencement thereof, the Performing Party may terminate this Agreement upon
written notice to the Non-performing Party.
10.7    Termination Upon Lack of Commercial Viability. If at any time during the
term of this Agreement Distributor or Manufacturer reasonably determine that due
to an event, change or circumstance outside of its reasonable control, the
continued sale and distribution of the Product is no longer commercial viable
[***], then Distributor or Manufacturer may provide written notice (the “Supply
Notice”) to the other Party of such determination and, if applicable, a
calculation of an [***] necessary for the continued distribution and sale of the
Product to remain commercially viable. Any such Supply Notice shall be
accompanied with reasonable documentation supporting [***] after the delivery of
the Supply Notice, Distributor and Manufacturer fail to negotiate an adjustment
to the Invoice Supply Price and other terms that would be necessary for the
continued distribution and sale of the Product to remain commercially viable,
which may include a retroactive price adjustment for inventory then held by
Distributor, either Party shall have the right to terminate this Agreement upon
[***] prior written notice delivered within [***] after such [***] period.
10.8    Purchase Orders; Sell-off. Upon either Party giving notice of
termination of this Agreement with such termination being effective prior to the
expiration of the Term, any outstanding Firm Order shall be automatically
cancelled, and Manufacturer shall have no further obligation to supply Product
to Distributor, provided that, [***],

34

--------------------------------------------------------------------------------

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

Distributor may, at its sole discretion, accept delivery of, and pay
Manufacturer for, all of such already finished Product under the terms of this
Agreement, and (iii) Distributor shall be authorized and permitted to sell any
inventory of Product during the [***] period immediately following the end of
the Term subject to its obligations to share profits with Manufacturer pursuant
to this Agreement. If Distributor has not sold all such remaining inventory
before the expiration of the sell-off period, Distributor shall, at
Manufacturer’s sole discretion and instruction, either return such excess
inventory to Manufacturer, at its sole cost and expense and, except as otherwise
provided in this Agreement, without payment therefor by Manufacturer, or destroy
such excess inventory and provide to Manufacturer a certification, executed by
one of its authorized officers, that such excess inventory has been destroyed.
10.9    Statutory Rights. Distributor acknowledges that it is cognizant of
certain state statutes that impose on a wholesaler, distributor or importer
specific duties and obligations with regard to the termination of a distribution
agreement. Notwithstanding the rights conferred under those statutes to a
distributor, Distributor hereby waives its rights thereunder with respect to a
valid termination pursuant to a right under this Agreement and in consideration
of its appointment hereunder covenants not to sue Manufacturer, or submit a
complaint to FDA or governmental authority, in the event of the termination of
this Agreement except for the purpose of enforcing Distributor’s rights under
this Agreement. This Section in no way affects the enforcement rights of
Distributor to recover amounts earned pursuant to this Agreement.
10.10    Obligations Following Expiration of this Agreement.
(a)    Purchase Orders; Sell-off. Provided that this Agreement has not been
terminated by either Party pursuant to Sections 10.2-10.7, of this Agreement and
provided the First Commercial Sale has occurred, (a) Manufacturer shall be
obligated to supply Distributor with any Product that is the subject of a
purchase order calling for delivery of the Product prior to the end of the Term
and that has not been delivered as of the end of the Term, and (b) Distributor
shall be permitted to sell any inventory of Product during the [***] period
immediately following the end of the Term subject to its obligations to share
profits with Manufacturer pursuant to this Agreement. If Distributor has not
sold all such remaining inventory before the expiration of the sell-off period,
Distributor shall, at Manufacturer’s sole discretion and instruction, either
return such excess inventory to Manufacturer, at its sole cost and expense and
without payment therefor by Manufacturer, or destroy such excess inventory and
provide to Manufacturer a certification, executed by one of its authorized
officers, that such excess inventory has been destroyed.
(b)    Failure to Supply Charges. Except with respect to a termination of this
Agreement by Distributor pursuant [***].

35

--------------------------------------------------------------------------------

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

10.11    Effects of Termination. Upon the expiration or termination of this
Agreement, (a) this Agreement shall thereafter have no effect, except as
provided in Section 12.2, (b) except as otherwise set forth herein, payment
obligations that have accrued and have been invoiced before the date of
expiration or termination shall remain due and payable in accordance with the
terms of this Agreement, and payment obligations that have accrued but have not
been invoiced as of the date of expiration or termination shall be invoiced and
paid in full within [***] of receipt of such invoice, (c) all rights granted by
Manufacturer to Distributor shall immediately cease (except with respect to any
applicable sell-off period under Sections 10.8 or 10.10(a)), and (d) except as
otherwise set forth herein, neither Party shall be relieved from liability for
any breach of any representation, warranty or agreement hereunder occurring
before such expiration or termination.
ARTICLE 11
CONFIDENTIALITY, PUBLIC ANNOUNCEMENTS AND DISCLOSURE
11.1    Confidentiality. Except to the extent expressly authorized by this
Agreement or otherwise agreed by the Parties in writing, until the later of (i)
the termination of this Agreement or (ii) ten (10) years after the date of
disclosure, each of Distributor and its Affiliates, on the one hand, and
Manufacturer and its Affiliates on the other (the “Recipient”), receiving or
learning of any Confidential Information of the other Party (the “Disclosing
Party”) in connection with this Agreement or the Bailment Agreement, shall keep
such information confidential and shall not publish or otherwise disclose or use
it for any purpose other than as provided for in this Agreement, except to the
extent that it can be established by the Recipient that the Confidential
Information:
(a)    was already known to the Recipient (other than under an obligation of
confidentiality) at the time of receipt by the Recipient, and the Recipient can
so demonstrate by documentary evidence to that effect;
(b)    was generally available to the public or otherwise part of the public
domain at the time of its disclosure to the Recipient;
(c)    became generally available to the public or otherwise part of the public
domain after its disclosure and other than through any act or omission in breach
of a confidentiality obligation of the Recipient;
(d)    was disclosed to the Recipient (other than under an obligation of
confidentiality) by a Third Party who had no obligation to the Disclosing Party
not to disclose such information to others; or
(e)    was independently discovered or developed by the Recipient without the
use of the Confidential Information of the Disclosing Party, and the Recipient
can so demonstrate by documentary evidence to that effect.

36

--------------------------------------------------------------------------------

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

11.2    Authorized Disclosure. Notwithstanding the foregoing, a Recipient may
disclose Confidential Information of the Disclosing Party to a Third Party to
the extent such disclosure is reasonably necessary to:
(a)    Prosecute or defend litigation;
(b)    Effectively exercise its rights and obligations under this Agreement;
(c)    Comply with applicable governmental laws and regulations, orders,
rulings, guidance documents, pronouncements, filing requirements and the like,
(d)    its Affiliates, and its and their employees, consultants, contractors and
agents; or
(e)    potential and actual investors, acquirors, licensees and other financial
or commercial partners solely for the purpose of evaluating or carrying out an
actual or potential investment, acquisition or collaboration,.
In the event a Recipient shall deem it necessary to disclose, pursuant to this
Section 11.2, Confidential Information of the Disclosing Party, the Recipient
(i) shall in the case of disclosures pursuant to Sections 11.2(a)-(c), to the
extent possible, give reasonable advance notice of such disclosure to the
Disclosing Party, (ii) shall use reasonable efforts to minimize the scope of
such disclosure, and (iii) shall cooperate with the Disclosing Party to take
reasonable measures to ensure confidential treatment of such information,
including, but not limited to, by ensuring that the Third Party to whom the
Confidential Information is disclosed to is subject to obligations to maintain
such information in confidence and to use it only for the purposes for which it
is disclosed.
11.3    SEC Filings. Either Party may disclose the terms of this Agreement to
the extent required, in the reasonable opinion of such Party’s legal counsel, to
comply with applicable laws, including, without limitation, the rules and
regulations promulgated by the United States Securities and Exchange Commission.
Notwithstanding the foregoing, before disclosing this Agreement or any of the
terms hereof pursuant to this Section 11.3, the Parties will reasonably consult
with one another on the terms of this Agreement to be redacted in making any
such disclosure. If a Party discloses this Agreement or any of the terms hereof
in accordance with this Section 11.3, such Party agrees, at its own expense, to
request confidential treatment of portions of this Agreement or such terms, as
may be reasonably requested by the other Party.
11.4    Public Announcements. Following the Commencement Date, either Party may
issue a press release or make a public announcement or statement (including,
without limitation, a presentation to investor meetings) concerning the
existence or terms of this Agreement, and the disclosing Party shall (i) provide
[***] advance notice and text of such press release, public announcement or
statement to the other Party, and (ii) obtain the written approval of the other
Party, [***] on the nature, text and timing of such press release, public
announcement or statement. In addition, Manufacturer may issue a press release
at any time without notice to, or consent of, Distributor. Either Party shall
have the right to make any public announcement or other disclosure required by
applicable law after such Party has

37

--------------------------------------------------------------------------------

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

provided to the other Party a copy of such announcement or disclosure [***] in
advance of making such announcement or disclosure and an opportunity to comment
thereon (to the extent legally permitted). The disclosing Party shall reasonably
consider the other Party’s comments. Each Party agrees that it shall cooperate
fully with the other with respect to all disclosures regarding this Agreement to
the Securities Exchange Commission (in accordance with Section 11.3) and any
other governmental or regulatory agencies, including requests for confidential
treatment of proprietary information of either Party included in any such
disclosure. Once any written statement is approved for disclosure by the Parties
or information is otherwise made public in accordance with this Section 11.4
after the Commencement Date, either Party may make a subsequent public
disclosure of the same contents of such statement in the same context as such
statement without further approval of the other Party. Notwithstanding anything
to the contrary contained herein, in no event shall either Party disclose any
financial information of the other, without the prior written consent of such
other Party (to the extent legally permitted), unless such financial information
already has been publicly disclosed by the Party owning the financial
information or otherwise has been made part of the public domain by no breach of
a Party of its obligations under this Section 11.4.
11.5    Injunctive Relief. Anything herein to the contrary notwithstanding, the
Parties acknowledge that any breach of the provisions of this Article 11 could
cause irreparable harm and significant injury, which may be difficult to
ascertain, and are not susceptible to monetary damages. Accordingly, the Parties
agree that the Disclosing Party shall have the right to seek the issuance of an
ex parte restraining order or injunction to prevent any breach or continuing
violation of the Recipient’s obligations hereunder, in addition to (and not in
substitution of) any other remedies that may be available to the Disclosing
Party at law or in equity.
ARTICLE 12
MISCELLANEOUS
12.1    Insurance. Each Party shall procure and maintain in full force and
effect at its own expense during the term of this Agreement and, provided a
First Commercial Sale has occurred, for a period of [***] following the
termination or expiration of this Agreement, a program of insurance which
includes the minimum required insurance described in Exhibit 12.1. Such
insurance shall be provided by an insurer with an [***]. Each Party shall
provide the other Party with a certificate of insurance evidencing such coverage
upon request of the other Party. On such certificate of insurance, each Party
shall cause the other Party to be listed as an “additional insured” as required
by agreement. Such “additional insured” status shall be limited to instances
where there is an indemnifiable claim pursuant to the terms of this Agreement or
the Bailment Agreement. In the event of a claim for which there is an
indemnification obligation, and for which the indemnified Party is deemed an
“additional insured,” the indemnifying Party’s insurance shall be deemed primary
and non-contributory with any insurance maintained by the indemnified Party.
12.2    Survival. The provisions of Sections 2.4-2.6, 3.4 - 3.9, 5.2(c) and (d),
6.7, 6.8, 8.4 and 8.5, and Articles 4, 7, 9, 10, 11 and 12 and those provisions
of this Agreement dealing with rights and obligations after termination of this
Agreement shall survive termination of this Agreement to the extent necessary to
give effect to such provisions.

38

--------------------------------------------------------------------------------

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

12.3    Independent Contractor Status; No Joint Venture or Partnership. Neither
Party shall have any authority to obligate the other in any respect or to hold
itself out as having any such authority. All personnel of Manufacturer shall be
solely employees of Manufacturer and shall not represent themselves as employees
of Distributor, and all personnel of Distributor shall be solely employees of
Distributor and shall not represent themselves as employees of Manufacturer.
Nothing herein shall be deemed to create a partnership or joint venture between
the Parties.
12.4    Binding Effect; Benefits; Assignment.
(a)    This Agreement shall inure to the benefit of and be binding upon the
Parties hereto and their respective permitted successors and assigns. Nothing
contained herein shall give to any other Person any benefit or any legal or
equitable right, remedy or claim.
(b)    Subject to Section 12.4(c) and Section 12.4(d), this Agreement shall not
be assignable by either Party without the prior written consent of the other
Party, except that a Party shall be permitted to assign this Agreement without
the prior written consent of the other Party to a Person acquiring all or
substantially all of such Party’s assets or voting stock. Such assignment shall
be subject to the assignee agreeing in writing to assume the benefits and
obligations of this Agreement. A Party shall provide the other Party with prompt
notice of any such sale, or other Change of Control of such Party promptly
following consummation thereof.
(c)    Manufacturer shall be entitled, without the prior written consent of
Distributor, to assign all of its rights, duties, restrictions and obligations
under this Agreement to an Affiliate; provided the Affiliate expressly assumes
in writing those rights, duties, restrictions and obligations of Manufacturer
under this Agreement and Manufacturer expressly agrees in writing to continue to
be bound by the duties, restrictions and obligations of Manufacturer under this
Agreement.
(d)    Distributor may, with the prior written consent of Manufacturer, assign
all of its rights, duties, restrictions and obligations under this Agreement to
an Affiliate; provided the Affiliate expressly assumes in writing those rights,
duties, restrictions and obligations of Distributor under this Agreement and
Distributor expressly agrees in writing to continue to be bound by the duties,
restrictions and obligations of Distributor under this Agreement.
(e)    Any purported assignment of this Agreement in violation of the foregoing
shall be null and void ab initio and of no force or effect.
12.5    Entire Agreement; Amendments. This Agreement, including all Exhibits,
the Bailment Agreement, the Pharmacovigilance Agreement, and Quality Agreement
constitute the entire agreement between the Parties with respect to the subject
matter of this Agreement, and all prior agreements, understandings, promises and
representations, whether written or oral, with respect thereto are superseded
hereby. Each of the Parties acknowledges that in deciding to enter into this
Agreement and to consummate the transaction contemplated hereby none of them has

39

--------------------------------------------------------------------------------

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

relied upon any statements or representations, written or oral, other than those
explicitly set forth herein or therein. No subsequent alteration, amendment,
change or addition to this Agreement shall be binding upon the Parties hereto
unless reduced to writing and signed by the respective authorized officers of
the Parties.
12.6    Severability. In the event that any one or more of the provisions (or
any part thereof) contained in this Agreement or in any other instrument
referred to herein, will, for any reason, be held to be invalid, illegal or
unenforceable in any respect, the remaining provisions of this Agreement will
remain in full force and effect. If any of the terms or provisions of this
Agreement are in conflict with any applicable statute or rule of law, then such
terms or provisions will be deemed inoperative to the extent that they may
conflict therewith and will be deemed to be modified to conform with such
statute or rule of law. In the event that the terms and conditions of this
Agreement are materially altered as a result of this Section 12.6, the Parties
will renegotiate the terms and conditions of this Agreement to resolve any
inequities.
12.7    Remedies. Unless otherwise expressly provided, all remedies hereunder
are cumulative, and in addition to any other remedies provided for by law and
may, to the extent permitted by law, be exercised concurrently or separately,
and the exercise of any one remedy shall not be deemed to be an election of such
remedy or to preclude the exercise of any other remedy.
12.8    Notices. Any notice, request, consent or communication (collectively, a
“Notice”) under this Agreement shall be effective if it is in writing and (i)
personally delivered, (ii) sent by certified or registered mail, postage
prepaid, return receipt requested, (iii) sent by an internationally recognized
overnight delivery service, with delivery confirmed, or (iv) sent by facsimile
or electronic mail, with receipt confirmed and hard copy delivered by regular
mail; addressed as set forth in this Section 12.8 or to such other address as
shall be furnished by either Party hereto to the other Party hereto. A Notice
shall be deemed to have been given as of (i) the date when personally delivered,
(ii) [***] after being deposited with the United States Postal Service,
certified or registered mail, properly addressed, return receipt requested,
postage prepaid, (iii) two Business Days after being delivered to said overnight
delivery service properly addressed, or (iv) immediately upon receiving
confirmation of receipt of the facsimile or electronic mail, as the case may be.
If to Manufacturer:
[***]

 

40

--------------------------------------------------------------------------------

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

If to Distributor:
[***]

12.9    Waivers. No failure or delay by either Party in exercising any right or
remedy provided by law under or pursuant to this Agreement shall impair such
right or remedy or operate or be construed as a waiver or variation of it or
preclude its exercise at any subsequent time and no single or partial exercise
of any such right or remedy shall preclude any other or further exercise of it
or the exercise of any other right or remedy.
12.10    Counterparts. This Agreement may be executed in any number of
counterparts (including by facsimile or electronic document), and execution by
each of the Parties of any one of such counterparts will constitute due
execution of this Agreement. Each such counterpart

41

--------------------------------------------------------------------------------

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

hereof shall be deemed to be an original instrument, and all such counterparts
together shall constitute but one agreement.
12.11    Headings. The article and section headings contained in this Agreement
are for reference purposes only and shall not affect in any way the meaning or
interpretation of this Agreement.
12.12    Construction. The Parties expressly agree that any rule of construction
to the effect that ambiguities are to be resolved against the drafting Party
shall not be applied in the construction or interpretation of this Agreement.
The language in all parts of this Agreement shall be construed, in all cases,
according to its fair meaning. The words “hereof,” “herein,” “hereto” and
“hereunder” and words of similar import, when used in this Agreement, shall
refer to this Agreement as a whole and not to any particular provision of this
Agreement. The terms defined in the singular shall have a comparable meaning
when used in the plural, and vice versa. Whenever used herein, the words
“include,” “includes” and “including” shall mean “include, without limitation,”
“includes, without limitation” and “including, without limitation,”
respectively. The masculine, feminine or neuter gender and the singular or
plural number shall each be deemed to include the others whenever the context so
indicates.
12.13    Governing Law and Jurisdiction. This Agreement shall be governed by the
laws of the State of New York without regard to the conflicts of law provisions
thereof. The Parties irrevocably agree that the federal district courts in the
State of New York shall have exclusive jurisdiction to deal with any disputes
arising out of or in connection with this Agreement and that, accordingly, any
proceedings arising out of or in connection with this Agreement shall be brought
in the United States District Court for the Southern District of New York.
Notwithstanding the foregoing, if there is any dispute for which the federal
district courts in the Southern District of New York do not have subject matter
jurisdiction, the state courts in New York, shall have jurisdiction. In
connection with any dispute arising out of it in connection with this Agreement,
each Party hereby expressly consents and submits to the personal jurisdiction of
the federal and state courts in County, City, and State of New York. Each Party
hereto agrees that A RIGHT TO TRIAL BY JURY IS HEREBY WAIVED any that such
proceeding will be conducted solely in the English language.
12.14    Expenses. Each Party will pay all of its own fees and expenses
(including all legal, accounting and other advisory fees) incurred in connection
with the negotiation and execution of this Agreement and the arrangements
contemplated hereby, except as specifically provided herein.
12.15    Informal Dispute Resolution. Unless otherwise expressly provided for
herein, any claim or controversy between the Parties arising out of or relating
to the execution, interpretation and performance of this Agreement (including
the validity, scope and enforceability of this provision) will be identified in
writing and presented to the other Party. Within [***] after delivery of such
notice of dispute, the Chief Executive Officer of Manufacturer and [***] (or
another executive of a Party or an Affiliate designated by such [***], as
applicable) (the “Designated Officers”) will meet (either in person or via
telephone conference) at a mutually acceptable time and place, and thereafter as
often as they reasonably deem necessary, to attempt to resolve the dispute in
good

42

--------------------------------------------------------------------------------

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

faith. All reasonable requests for information made by one Party to another will
be honored. All negotiations pursuant to this clause are confidential and will
be treated as compromise and settlement negotiations for purposes of applicable
rules of evidence. If such Designated Officers cannot resolve such dispute
within [***] after such initial meeting, then each Party reserves its right to
any and all remedies available under law or equity with respect to any other
dispute. Notwithstanding anything to the contrary herein, each Party may seek
immediate or other equitable relief against the other Party at any time to
enforce their proprietary rights in confidential information or other
intellectual property rights.

[THE REST OF THIS PAGE IS INTENTIONALLY LEFT BLANK.]

43

--------------------------------------------------------------------------------

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

IN WITNESS WHEREOF, the undersigned have executed this Agreement as of the date
hereof.

 
 
AMAG PHARMACEUTICALS, INC.
 
 
 
 
 
 
 
By:
 
/s/ William K. Heiden
 
 
Name:
 
William K. Heiden
 
 
Title:
 
President and Chief Executive Officer
 
 
 
 
 
 

 
 
PRASCO, LLC
 
 
 
 
 
 
 
By:
 
[***]
 
 
Name:
 
[***]
 
 
Title:
 
[***]
 
 
 
 
 
 

 

[Signature Page to Distribution and Supply Agreement]

--------------------------------------------------------------------------------

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

EXHIBIT 1.49

MANUFACTURING COSTS

[***]

--------------------------------------------------------------------------------

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

EXHIBIT 1.63

DESCRIPTION OF PRE-BOOKING ACTIVITIES

[***]

--------------------------------------------------------------------------------

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

 
EXHIBIT 2.3(d)

STORAGE AND SHIPPING REQUIREMENTS

[***]

--------------------------------------------------------------------------------

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

EXHIBIT 3.4(a)

PERCENTAGE OF NET DISTRIBUTABLE PROFITS

[***]

--------------------------------------------------------------------------------

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

EXHIBIT 3.4(b)

ACCRUAL ROLLFORWARD REPORT

[***]

--------------------------------------------------------------------------------

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

EXHIBIT 3.5(a)(i)

INVENTORY ACTIVITY REPORT

[***]

--------------------------------------------------------------------------------

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

EXHIBIT 3.5(a)(ii)
QUARTERLY REPORT

[***]

--------------------------------------------------------------------------------

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

EXHIBIT 5.1(b)

INITIAL LAUNCH QUANTITIES

[***]

--------------------------------------------------------------------------------

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

EXHIBIT 5.1(d)

INCREMENTAL ORDER SIZES

[***]

MINIMUM ORDERS

[***]

--------------------------------------------------------------------------------

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

EXHIBIT 12.1

INSURANCE

[***]